BDNF (Brain-Derived Neurotrophic Factor)

1. Overview

Brain-derived neurotrophic factor (BDNF) is the most abundant and arguably most intensively studied member of the mammalian neurotrophin family, which also includes nerve growth factor (NGF), neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4). First purified from pig brain by Yves-Alain Barde and Hans Thoenen in 1982 and cloned in 1989, BDNF is a secreted, basic, homodimeric protein with a molecular mass of approximately 27.8 kDa in its mature form [1]. Each monomer comprises 119 amino acids arranged into a cystine-knot fold stabilized by three intrachain disulfide bonds, with two monomers associating non-covalently into the bioactive dimer that engages its tyrosine-kinase receptor, tropomyosin receptor kinase B (TrkB), on the surface of responsive neurons and glial cells.

BDNF is encoded on human chromosome 11p14.1 by a gene with a complex structure that includes at least 11 exons and multiple alternative promoters. The gene is translated into a 247-amino-acid preproBDNF polypeptide that is processed through the secretory pathway: the signal peptide is cleaved in the endoplasmic reticulum, and the resulting proBDNF (approximately 32 kDa) is either cleaved intracellularly by furin and proprotein convertases (notably PC1/PC3) in the trans-Golgi network and secretory granules to yield mature BDNF (mBDNF), or secreted as proBDNF and subsequently cleaved extracellularly by plasmin, the tissue plasminogen activator system, and matrix metalloproteinases (MMP-2, MMP-3, MMP-7, and MMP-9). The regulated balance between secreted proBDNF and mBDNF is a central determinant of functional output, because the two molecular species signal through different receptors with opposing biological effects [7][8][9].

Despite decades of preclinical promise, BDNF itself has never been approved as a clinical drug. Recombinant methionyl-BDNF failed in late-stage trials for amyotrophic lateral sclerosis and diabetic neuropathy in the late 1990s, primarily because the 13.5 kDa basic protein is effectively BBB-impermeable, has a plasma half-life of less than 10 minutes, and exhibits extremely limited tissue diffusion after local injection. These translational obstacles have redirected the field toward three alternative strategies: (i) small-molecule TrkB agonists and positive allosteric modulators such as 7,8-dihydroxyflavone (7,8-DHF) [13] and LM22A-4 [14]; (ii) indirect BDNF-releasing therapeutics such as ketamine, selective serotonin reuptake inhibitors, and classical psychedelics, which converge on TrkB at a cholesterol-binding transmembrane pocket [20][22][24]; and (iii) local, targeted gene therapy, exemplified by AAV2-BDNF currently in a Phase 1 trial for Alzheimer's disease at UCSD (NCT05040217) [19][25].

Molecular Weight

27.8 kDa (homodimer of two ~13.5 kDa subunits)

Precursor Length

247 amino acids (preproBDNF); proBDNF ~32 kDa; mature BDNF 119 amino acids

Gene

BDNF on chromosome 11p14.1; at least 11 exons with alternative splicing

Receptors

TrkB (NTRK2) high-affinity; p75NTR (NGFR) low-affinity; sortilin co-receptor for proBDNF

Cleavage

Intracellular by furin/PC1 to mBDNF; extracellular conversion of proBDNF by plasmin and matrix metalloproteinases (MMP-2, MMP-3, MMP-7, MMP-9)

BBB Permeability

Intact BDNF is BBB-impermeable; intranasal, intrathecal, ICV, or gene-therapy routes required for CNS delivery

Half-life

Less than 10 minutes in plasma; tissue half-life substantially longer

Discovery

Purified from pig brain by Yves-Alain Barde and Hans Thoenen (1982); cloned 1989

2. Molecular Biology and Biosynthesis

The Neurotrophin Family

BDNF is one of four mammalian neurotrophins (NGF, BDNF, NT-3, NT-4) that share approximately 50 percent amino acid identity, a conserved cystine-knot fold, and a common signaling architecture built around three tropomyosin receptor kinases (TrkA, TrkB, TrkC) and the pan-neurotrophin receptor p75NTR. BDNF binds TrkB with nanomolar affinity, NT-4 also binds TrkB, while NGF is selective for TrkA and NT-3 for TrkC (though NT-3 can weakly engage TrkA and TrkB). All neurotrophins bind p75NTR with similar low affinity in their mature forms, but proneurotrophins bind p75NTR with substantially higher affinity when the co-receptor sortilin is present.

From preproBDNF to mBDNF

The BDNF gene is transcribed from multiple alternative promoters into at least eight protein-coding transcripts that all converge on a single open reading frame. Translation produces the 247-amino-acid preproBDNF, which enters the endoplasmic reticulum through a 16-amino-acid signal peptide. Cleavage of the signal peptide yields proBDNF (approximately 32 kDa), which dimerizes and is trafficked to the trans-Golgi network. At this stage, proBDNF can be cleaved intracellularly by furin or PC1/PC3 to yield mBDNF, or packaged intact into regulated-secretion vesicles and released into the extracellular space as proBDNF. Extracellular proBDNF is subsequently cleaved by plasmin, tissue plasminogen activator (tPA)-plasminogen cascades, and several matrix metalloproteinases (MMP-2, MMP-3, MMP-7, MMP-9) to generate mBDNF [7][9].

Val66Met (rs6265) Polymorphism

A common single-nucleotide polymorphism in the human BDNF gene, rs6265, produces a valine-to-methionine substitution at codon 66 of the prodomain (Val66Met). The Met allele is carried by approximately 25-32 percent of individuals of European ancestry and up to 50 percent of individuals of Asian ancestry. Egan and colleagues (2003) demonstrated that Met-BDNF protein shows impaired intracellular trafficking to the regulated secretory pathway and reduced activity-dependent release, although constitutive secretion and mature protein levels are largely preserved [4]. The polymorphism is associated with smaller hippocampal volume, reduced episodic memory performance, altered fMRI hippocampal activation during encoding, and an increased susceptibility to depression in the context of early-life stress [4][5][18]. A 2023 meta-analysis found no significant main-effect association with major depressive disorder, consistent with a gene-environment interaction model rather than a simple genetic risk factor [18][23].

3. Mechanism of Action

TrkB Signaling (Survival, Plasticity, and LTP)

Binding of mBDNF dimer to the extracellular immunoglobulin-like domain of TrkB triggers receptor homodimerization and trans-autophosphorylation of tyrosine residues in the intracellular kinase domain (Y515, Y705, Y706, Y816 in human TrkB). Phosphorylated TrkB recruits three canonical adaptor systems:

• Shc/Grb2/SOS activation of the Ras-Raf-MEK-ERK (MAPK) cascade, which drives CREB-dependent gene expression, immediate-early gene induction (Arc, Egr1, c-Fos), and neurite outgrowth.
• PI3K-Akt-mTOR signalling, which controls protein translation, dendritic spine growth, and pro-survival responses through phosphorylation of BAD, FOXO, and GSK3β.
• PLCγ1-IP3-DAG-PKC signalling, which mobilizes intracellular calcium and activates CaMKII-dependent programs essential for hippocampal long-term potentiation (LTP).

BDNF-TrkB signalling is critical for the protein-synthesis-dependent late phase of LTP (L-LTP). Korte, Bonhoeffer and colleagues showed that BDNF-heterozygous mice exhibit impaired L-LTP that can be rescued either by acute application of recombinant BDNF or by adenoviral reintroduction of BDNF into the CA1 region [2][3]. These findings established BDNF as a necessary permissive factor for activity-dependent synaptic strengthening in the hippocampus.

p75NTR-Sortilin Signaling (Apoptosis and LTD)

Secreted proBDNF binds a receptor complex of p75NTR and sortilin with subnanomolar affinity and activates pro-apoptotic signaling via JNK, RhoA, NFκB, and caspase cascades [7]. In the hippocampus, proBDNF-p75NTR signaling preferentially facilitates long-term depression (LTD) rather than LTP [8]. The net biological output of the BDNF system therefore depends on the balance between proBDNF and mBDNF, the activities of the cleaving proteases, and the relative expression of TrkB, p75NTR and sortilin in a given cell. Lu, Pang and Woo framed this bidirectional system as the neurotrophin "yin-yang" model [9], a concept that continues to structure BDNF research and motivates selective pharmacological targeting of TrkB over p75NTR.

Antidepressant and Psychedelic Convergence on TrkB

Until 2021, the prevailing view was that classical antidepressants (SSRIs, SNRIs, tricyclics) and rapid-acting antidepressants (ketamine, esketamine) increase BDNF expression and release indirectly, via serotonergic, glutamatergic, and mTOR-mediated pathways. Autry, Monteggia and colleagues (2011) showed that ketamine's rapid antidepressant-like behavioral effects require immediate de novo BDNF translation: ketamine-mediated NMDAR blockade deactivates eEF2 kinase, dephosphorylates eEF2, and desuppresses dendritic BDNF mRNA translation [15]. Casarotto, Castrén and colleagues (2021) reframed this relationship by showing that fluoxetine, imipramine, moclobemide and ketamine all bind directly to the transmembrane domain of TrkB dimers at a cholesterol-sensitive site, allosterically facilitating BDNF-induced signaling [20]. A 2023 Nature Neuroscience study by Moliner, Castrén and colleagues extended the paradigm by demonstrating that LSD and psilocin bind the same TrkB pocket with approximately 1000-fold higher affinity than classical antidepressants, and that their plasticity and antidepressant-like effects depend on TrkB engagement and can be dissociated from 5-HT2A-mediated hallucinogenic effects [22]. Castrén and Monteggia synthesized these findings in a 2024 review arguing that diverse plasticity-enhancing psychiatric drugs act as positive allosteric modulators of TrkB, placing the BDNF-TrkB axis at the molecular core of antidepressant action [24].

4. Researched Applications

Major Depressive Disorder

Evidence level: Moderate (biomarker and convergent mechanistic evidence)

Serum and plasma BDNF are reduced in patients with untreated major depressive disorder and generally normalize with effective antidepressant treatment. The large meta-analysis by Molendijk and colleagues (179 associations, N=9484) confirmed this state-marker pattern but found no robust correlation between BDNF levels and symptom severity, suggesting BDNF reflects treatment-related neuroplasticity rather than primary pathophysiology [16]. Mechanistic evidence from Autry et al., Casarotto et al. and Moliner et al. positions BDNF-TrkB as a direct pharmacological target of classical and rapid-acting antidepressants [15][20][22]. The BDNF Val66Met polymorphism interacts with stressful life events to confer depression risk in gene-environment interaction analyses [18].

Alzheimer's Disease

Evidence level: Preliminary (Phase 1 open-label trial ongoing)

Nagahara, Tuszynski and colleagues (2009) demonstrated that lentiviral or AAV-delivered BDNF into the entorhinal cortex of APP transgenic mice, aged rats, aged rhesus monkeys, and lesioned primates reverses synapse loss, normalizes aberrant gene expression, and restores learning and memory, with effects independent of amyloid plaque burden [12]. Preclinical MRI-guided AAV2-BDNF delivery into non-human primate entorhinal cortex was reported in 2018 [19]. A Phase 1 open-label clinical trial (NCT05040217) delivering AAV2-BDNF to the entorhinal cortex in patients with mild AD and amnestic MCI is ongoing at UCSD; early findings in six mild-AD participants with follow-up of 1-18 months reported no serious adverse events attributable to the study procedure, and FDG-PET showed increased cortical metabolism in the treated entorhinal region, reversing the typical AD decline pattern [25].

Huntington's Disease

Evidence level: Preclinical (multiple disease models)

A hallmark of Huntington's disease pathophysiology is reduced corticostriatal BDNF delivery: wild-type huntingtin normally sequesters the REST transcription factor in the cytoplasm, permitting BDNF transcription in cortical neurons, whereas mutant huntingtin releases REST to the nucleus where it represses BDNF and other neuronal genes [10]. Postmortem studies confirmed reduced BDNF protein in HD cortex [11]. In R6/2 and BACHD mouse models of Huntington's disease, systemic BDNF infusion and the small-molecule BDNF mimetic LM22A-4 reduce striatal atrophy, preserve medium spiny neurons, and improve motor function [14], although some reports have challenged the specificity of small-molecule TrkB agonists, highlighting the need for further validation.

Exercise, Cognition, and Neuroplasticity

Evidence level: Moderate (human biomarker and preclinical causal data)

Voluntary wheel running and aerobic exercise robustly upregulate hippocampal BDNF in rodents. Vaynman, Ying and Gomez-Pinilla (2004) showed that blocking hippocampal BDNF-TrkB signaling with a TrkB-IgG fusion protein abolished exercise-induced improvements in spatial learning and the upregulation of synaptic plasticity markers, establishing BDNF as a necessary mediator of the exercise-cognition link [6]. The 2014 meta-analysis by Szuhany, Bugatti and Otto (29 studies, N=1111) reported that a single exercise session produces a moderate increase in circulating BDNF (Hedges g = 0.46), with regular training amplifying the acute response (g = 0.59) and producing a small effect on resting BDNF (g = 0.27) [17]. BDNF is now a central node in theories of how exercise, environmental enrichment, and cognitive engagement promote brain health and resilience.

Rett Syndrome and Neurodevelopmental Disorders

Evidence level: Preclinical

MeCP2, the gene mutated in Rett syndrome, is a transcriptional regulator of BDNF. Mecp2-mutant mice show reduced BDNF expression and neurological phenotypes partially rescued by BDNF overexpression or TrkB agonists. The BDNF mimetics 7,8-DHF and LM22A-4 have been reported to ameliorate dendritic spine phenotypes and atypical behaviours in Rett mouse models, providing a mechanistic link between MeCP2, BDNF, and neurodevelopmental dysfunction.

Stroke, Traumatic Brain Injury, and Demyelinating Disease

Evidence level: Preclinical

TrkB agonists including LM22A-4 confer neuroprotection and preserve myelin integrity in rodent models of pediatric traumatic brain injury, hypoxic-ischemic stroke, and demyelinating injuries of the corpus callosum. LM22A-4 also increases oligodendroglial populations during myelin repair in the corpus callosum, suggesting a role for BDNF-TrkB signaling in remyelination.

Peripheral Nervous System and Metabolic Effects

Evidence level: Preclinical to early clinical (failed ALS/neuropathy trials)

Recombinant BDNF was tested in Phase 2 and Phase 3 trials for ALS and diabetic peripheral neuropathy in the 1990s but did not meet primary efficacy endpoints, largely attributed to poor tissue penetration, short half-life, and limited access to motoneurons after subcutaneous administration. These negative clinical results have shaped the contemporary emphasis on small-molecule mimetics, allosteric modulators, and local gene therapy.

5. Clinical Evidence Summary

6. Dosing in Research

Direct administration of recombinant BDNF in humans is not clinically used. The following table summarizes representative research doses for BDNF and its small-molecule mimetics, along with the investigational AAV2-BDNF gene therapy protocol.

7. Pharmacokinetics

Recombinant BDNF

• Plasma half-life: Less than 10 minutes following intravenous administration in rodents and primates, reflecting rapid proteolytic degradation and distribution into tissues.
• BBB permeability: Effectively zero for intact BDNF under physiological conditions; BDNF is a positively charged, ~14 kDa monomer (~28 kDa dimer) that does not cross the BBB through receptor-mediated transport at clinically useful rates.
• Intracerebroventricular (ICV): ICV infusion of approximately 1 μg/day in rats produces measurable increases in hippocampal BDNF-related gene expression and behavioural changes but with sharply limited diffusion from the ventricular system into deep parenchyma.
• Intrathecal delivery: Tested in ALS and diabetic neuropathy trials; limited cord penetration and off-target effects such as paresthesias.
• Intranasal delivery: Experimental in rodents; microgram-range doses reach brain tissue via direct nose-to-brain transport along olfactory and trigeminal nerves, though human pharmacokinetic data are limited.

7,8-Dihydroxyflavone (7,8-DHF)

• Route: Oral (po), intraperitoneal (ip), or intravenous in animal studies.
• Bioavailability: Orally bioavailable in rodents; crosses the BBB.
• Plasma half-life: Approximately 1-2 hours in mice; first-pass glucuronidation limits systemic exposure. Prodrug formulations (e.g., R13) have been developed to improve pharmacokinetics.
• CNS activity: Activates TrkB phosphorylation in the hippocampus, cortex, and striatum at 5-50 mg/kg doses in mice.

LM22A-4

• Route: Intraperitoneal, subcutaneous, or intranasal in rodents; oral and parenteral formulations have been explored.
• CNS exposure: Crosses the BBB after systemic administration; intranasal administration markedly increases brain exposure in rodents.
• Target engagement: Binds TrkB at the BDNF loop-II-mimicking pharmacophore with nanomolar affinity and acts as a partial agonist.

AAV2-BDNF Gene Therapy

• Delivery: Single MRI-guided stereotactic intraparenchymal injection into the entorhinal cortex, typically bilateral.
• Expression kinetics: Transgene expression detectable within weeks and persisting for months to years in non-human primates.
• Distribution: Widespread anterograde transport along entorhinal projections to the hippocampus in rodent and primate models.

8. Comparative Effectiveness

Small-Molecule TrkB Agonists

• 7,8-Dihydroxyflavone (7,8-DHF): Full agonist-like activity in many assays; orally bioavailable and BBB-penetrant; extensively studied across more than 180 preclinical studies in Alzheimer's, Parkinson's, depression, memory, and bone loss models [13].
• LM22A-4: Designed as a partial TrkB agonist based on the BDNF loop-II pharmacophore; validated in models of stroke, traumatic brain injury, Huntington's disease, Rett syndrome, optic neuropathy, and demyelination [14].
• Specificity concerns: Some independent groups have reported failure to reproduce TrkB activation by 7,8-DHF or LM22A-4 in specific assay conditions, prompting careful attention to dose, assay, and readout when interpreting preclinical data.

Recombinant BDNF vs. Gene Therapy

• Recombinant BDNF: Historical failure in ALS and diabetic-neuropathy Phase 3 trials; limited by pharmacokinetics and penetration.
• AAV-BDNF gene therapy: Overcomes pharmacokinetic limitations by producing sustained local BDNF secretion at the target site; the UCSD Phase 1 trial is the first clinical test of this strategy in Alzheimer's disease [19][25].

Antidepressants and Psychedelics as BDNF-TrkB Modulators

• SSRIs and classical antidepressants: Chronic dosing increases hippocampal BDNF expression; Casarotto et al. 2021 showed direct low-affinity binding to the TrkB transmembrane domain [20].
• Ketamine and esketamine: Rapid antidepressant effects depend on de novo BDNF translation [15] and postsynaptic TrkB activation [21].
• Classical psychedelics (LSD, psilocin): Bind TrkB with ~1000-fold higher affinity than SSRIs, drive plasticity and antidepressant-like effects independently of 5-HT2A, and support the possibility of non-hallucinogenic neuroplastogens [22][24].

9. Safety and Adverse Events

Recombinant BDNF (Historical Human Trials)

• ALS Phase 3 (rhBDNF, subcutaneous, 1990s): No clear efficacy; common adverse events included injection-site reactions and mild paresthesias. Intrathecal administration produced sensory paresthesias related to dose.
• Diabetic neuropathy trials: Largely negative for efficacy; similar tolerability profile.

Small-Molecule TrkB Agonists

• 7,8-DHF and LM22A-4: Preclinical safety data are generally favourable, with no consistent organ-specific toxicity at therapeutic doses in rodents. No human safety data are available for either compound beyond supplement-grade 7,8-DHF use, which is not a medical recommendation.

AAV2-BDNF Gene Therapy

• UCSD Phase 1 (NCT05040217): As of reported interim findings, no serious adverse events attributable to the study procedure have been observed in six mild-AD participants followed for 1-18 months [25]. Theoretical risks include off-target BDNF expression, immune responses against AAV capsid or transgene, aberrant synaptic sprouting, and ectopic p75NTR signaling if proBDNF accumulates.

Theoretical Concerns with Chronic BDNF Elevation

• Epileptogenic potential: Sustained overexpression of BDNF has been associated with increased seizure susceptibility in some rodent models, reflecting BDNF's role in synaptic hyperexcitability.
• Pain and itch sensitization: BDNF is released from primary afferents and microglia in the spinal cord dorsal horn; systemic recombinant BDNF can produce hyperalgesia and paresthesias, contributing to tolerability issues in historical clinical trials.
• proBDNF-p75NTR imbalance: Strategies that upregulate total BDNF transcription without a corresponding increase in processing to mBDNF could inadvertently amplify pro-apoptotic proBDNF-p75NTR signaling.

10. BDNF as a Biomarker

Serum and plasma BDNF have been widely proposed as biomarkers for depression, bipolar disorder, schizophrenia, Alzheimer's disease, and exercise responsiveness. Key caveats are important for interpretation:

• Pre-analytic variability: Serum BDNF is substantially higher than plasma BDNF because platelet degranulation during clotting releases large amounts of stored BDNF. Sample handling, anticoagulant choice, processing time, and storage temperature strongly influence measured values.
• Peripheral-central correlation: Whether peripheral BDNF tracks central BDNF is debated; some rodent studies support concordant changes, but human data are mixed. Platelets may contribute the majority of circulating BDNF.
• State vs. trait: Meta-analyses show that serum BDNF differentiates untreated depression from health and rises with treatment, but does not correlate well with symptom severity or predict individual treatment response with clinical utility [16].
• Val66Met genotype: Should be considered in studies of BDNF biomarkers because the polymorphism influences activity-dependent release and possibly peripheral levels.

11. Future Directions

The BDNF-TrkB system occupies a central position in contemporary neuroplasticity research, and several directions are likely to shape the next decade:

• Selective TrkB positive allosteric modulators (PAMs): The recognition that diverse psychiatric drugs bind TrkB at a cholesterol-sensitive transmembrane site invites rational design of selective TrkB PAMs with improved potency, specificity, and pharmacokinetics [20][24].
• Non-hallucinogenic neuroplastogens: The dissociation of TrkB-mediated plasticity from 5-HT2A-mediated hallucinogenic effects of classical psychedelics raises the prospect of non-hallucinogenic antidepressants that exploit psychedelic-like neuroplasticity [22][24].
• Targeted gene therapy: The ongoing AAV2-BDNF trial at UCSD will inform whether locally delivered BDNF gene therapy can safely and efficaciously modify the trajectory of Alzheimer's disease and potentially other neurodegenerative conditions [25].
• proBDNF-selective tools: Selective inhibitors or neutralizing antibodies against proBDNF-p75NTR signaling may offer additional therapeutic leverage, especially in neurodegenerative and neuropathic-pain contexts where proBDNF accumulation is implicated.
• Val66Met stratification: Clinical trials of BDNF-modulating therapies are increasingly stratifying by rs6265 genotype, since Met-allele carriers may have different baseline plasticity and drug responses.

12. Related Peptides

See also: Cerebrolysin, Semax, Selank, Noopept, ARA-290 (Cibinetide), Cortagen

13. References

1. [1] Barde YA, Edgar D, Thoenen H. (1982). Purification of a new neurotrophic factor from mammalian brain. EMBO Journal. DOI PubMed
2. [2] Korte M, Griesbeck O, Gravel C, Carroll P, Staiger V, Thoenen H, Bonhoeffer T. (1996). Virus-mediated gene transfer into hippocampal CA1 region restores long-term potentiation in brain-derived neurotrophic factor mutant mice. Proceedings of the National Academy of Sciences. DOI PubMed
3. [3] Patterson SL, Abel T, Deuel TA, Martin KC, Rose JC, Kandel ER. (1996). Recombinant BDNF rescues deficits in basal synaptic transmission and hippocampal LTP in BDNF knockout mice. Neuron. DOI PubMed
4. [4] Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR. (2003). The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. DOI PubMed
5. [5] Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF, Weinberger DR. (2003). Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. Journal of Neuroscience. DOI PubMed
6. [6] Vaynman S, Ying Z, Gomez-Pinilla F. (2004). Hippocampal BDNF mediates the efficacy of exercise on synaptic plasticity and cognition. European Journal of Neuroscience. DOI PubMed
7. [7] Teng HK, Teng KK, Lee R, Wright S, Tevar S, Almeida RD, Kermani P, Torkin R, Chen ZY, Lee FS, Kraemer RT, Nykjaer A, Hempstead BL. (2005). ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. Journal of Neuroscience. DOI PubMed
8. [8] Woo NH, Teng HK, Siao CJ, Chiaruttini C, Pang PT, Milner TA, Hempstead BL, Lu B. (2005). Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. Nature Neuroscience. DOI PubMed
9. [9] Lu B, Pang PT, Woo NH. (2005). The yin and yang of neurotrophin action. Nature Reviews Neuroscience. DOI PubMed
10. [10] Zuccato C, Cattaneo E. (2007). Role of brain-derived neurotrophic factor in Huntington's disease. Progress in Neurobiology. DOI PubMed
11. [11] Zuccato C, Marullo M, Conforti P, MacDonald ME, Tartari M, Cattaneo E. (2008). Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. Brain Pathology. DOI PubMed
12. [12] Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, Wang L, Blesch A, Kim A, Conner JM, Rockenstein E, Chao MV, Koo EH, Geschwind D, Masliah E, Chiba AA, Tuszynski MH. (2009). Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nature Medicine. DOI PubMed
13. [13] Jang SW, Liu X, Yepes M, Shepherd KR, Miller GW, Liu Y, Wilson WD, Xiao G, Blanchi B, Sun YE, Ye K. (2010). A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proceedings of the National Academy of Sciences. DOI PubMed
14. [14] Massa SM, Yang T, Xie Y, Shi J, Bilgen M, Joyce JN, Nehama D, Rajadas J, Longo FM. (2010). Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. Journal of Clinical Investigation. DOI PubMed
15. [15] Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM. (2011). NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. DOI PubMed
16. [16] Molendijk ML, Spinhoven P, Polak M, Bus BA, Penninx BW, Elzinga BM. (2014). Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484). Molecular Psychiatry. DOI PubMed
17. [17] Szuhany KL, Bugatti M, Otto MW. (2015). A meta-analytic review of the effects of exercise on brain-derived neurotrophic factor. Journal of Psychiatric Research. DOI PubMed
18. [18] Hosang GM, Shiles C, Tansey KE, McGuffin P, Uher R. (2014). Interaction between stress and the BDNF Val66Met polymorphism in depression: a systematic review and meta-analysis. BMC Medicine. DOI PubMed
19. [19] Nagahara AH, Wilson BR, Ivasyk I, Kovacs I, Rawalji S, Bringas JR, Pivirotto PJ, Sebastian WS, Samaranch L, Bankiewicz KS, Tuszynski MH. (2018). MR-guided delivery of AAV2-BDNF into the entorhinal cortex of non-human primates. Gene Therapy. DOI PubMed
20. [20] Casarotto PC, Girych M, Fred SM, Kovaleva V, Moliner R, Enkavi G, Biojone C, Cannarozzo C, Sahu MP, Kaurinkoski K, Brunello CA, Steinzeig A, Winkel F, Patil S, Vestring S, Serchov T, Diniz CRAF, Laukkanen L, Cardon I, Antila H, Rog T, Piepponen TP, Bramham CR, Normann C, Lauri SE, Saarma M, Vattulainen I, Castrén E. (2021). Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell. DOI PubMed
21. [21] Kim JW, Autry AE, Na ES, Adachi M, Björkholm C, Kavalali ET, Monteggia LM. (2021). Sustained effects of rapidly acting antidepressants require BDNF-dependent MeCP2 phosphorylation. Nature Neuroscience. DOI PubMed
22. [22] Moliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, Antenucci L, Kot EF, Goncharuk SA, Kaurinkoski K, Kuutti M, Fred SM, Elsilä LV, Sakson S, Cardon I, Mitkovski M, Arseniev AS, Ranesi F, Lambrechts A, Karelson M, Riva A, Saarma M, Vattulainen I, Kittel P, Rog T, Chapman D, Roth BL, Castrén E. (2023). Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nature Neuroscience. DOI PubMed
23. [23] Youssef MM, Underwood MD, Huang YY, Hsiung SC, Liu Y, Simpson NR, Bakalian MJ, Rosoklija GB, Dwork AJ, Arango V, Mann JJ. (2023). Association between the BDNF Val66Met polymorphism and major depressive disorder: a systematic review and meta-analysis. Frontiers in Psychiatry. DOI PubMed
24. [24] Castrén E, Monteggia LM. (2024). Rethinking the role of TRKB in the action of antidepressants and psychedelics. Trends in Neurosciences. DOI PubMed
25. [25] Tuszynski MH, Nagahara AH, Alberini CM, Gage FH, Bankiewicz KS, Miller JP, et al. (2025). A Phase I Clinical Trial of AAV2-BDNF Gene Therapy for Alzheimer's Disease: Findings. Annals of Neurology. DOI PubMed